Endovia Health Sciences Inc(EDVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:59 PM ET (Korea 9/5 08:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -68.97 | Insider Own | 0.01% | Shs Outstand | 6.4M | Perf Week | -14.78% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.4M | Perf Month | -40.81% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 4.45% | Short Float | 16.52% | Perf Quarter | -73.6% |
| Income | -0.03B | P/S | 1.66 | EPS this Y | - | Inst Trans | 1.98% | Short Ratio | 0.17 | Perf Half Y | -87.78% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -201.4% | Short Interest | 1.06M | Perf YTD | -90.44% |
| Book/sh | -3.82 | P/C | 7.05 | EPS past 3/5Y | 19.99% 42.21% | ROE | - | 52W High | -98.03% ($13.40) | Perf Year | -95.93% |
| Cash/sh | 0.04 | P/FCF | - | Sales past 3/5Y | -84.07% -49.84% | ROIC | - | 52W Low | 5.6% ($0.25) | Perf 3Y | -99.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.38% | Gross Margin | -191.86% | Volatility(W/M) | 12.11% 16.42% | Perf 5Y | -99.94% |
| Dividend TTM | - | EV/Sales | 7.69 | Sales Y/Y TTM | -83.63% | Oper. Margin | -1463.75% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.03 | EPS Q/Q | 91.47% | Profit Margin | -3033.6% | RSI (14) | 35.55 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.03 | Sales Q/Q | -100% | SMA20 | -27.14% ($0.36) | Beta | -1.2 | Target Price | $160 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/20 | SMA50 | -43.26% ($0.46) | Rel Volume | 0.01 | Prev Close | $0.27 |
| Employees | 2 | LT Debt/Eq | - | EPS/Sales Surpr. | - -53.24% | SMA200 | -86.26% ($1.89) | Avg Volume(3M) | 6.40M | Price | $0.26 |
| IPO | 2019/2/5 | Option/Short | No/Yes | Trades | 221 | Volume | 70,159 | Change | -1.68% |
Company
EDVA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
� Originally started as a beverage business and has now pivoted into a cannabinoid-based health and wellness platform. This US-listed company is restructuring its operations around three core pillars: pharmaceutical assets, veterinary therapeutics, and consumer wellness beverages. It is a micro-cap stock listed on a US stock exchange.
Over the past 1 year, on the lower side
98% below its 1-year high.
EDVA has weak earning power
-1463.75% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 4.5%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $2M.
EDVA $2M PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is EDVA?
EDVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EDVA?
The market cap of EDVA is approximately $2M, ranking 5,881 within its sector.
What is the 52-week high and low for EDVA?
EDVA has recorded a 52-week high of $13.40 and a low of $0.25.
